Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) announced that patient enrollment in its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway mark. Preliminary imaging data from the study show encouraging signal in acute MS lesions and potential sensitivity to gray matter lesions, according to the company.
The study is evaluating a novel PET imaging technique using the [¹⁸F]3F4AP tracer to directly assess demyelination, the process of myelin degradation that underlies multiple sclerosis. Quantum BioPharma believes this approach could enhance development of MS therapies, including its investigational candidate Lucid-MS, for which an Investigational New Drug (IND) submission for a Phase 2 trial was submitted to the FDA in March 2026.
For leaders in business and technology, this milestone underscores a growing intersection between advanced imaging technologies and neurodegenerative disease treatment. The ability to directly visualize demyelination in living patients could dramatically accelerate clinical trials by providing a more objective and sensitive biomarker for drug efficacy. This is particularly important for MS, where current imaging techniques often fail to detect subtle changes in gray matter lesions, which are increasingly recognized as critical drivers of disability progression.
Quantum BioPharma is a biopharmaceutical company building a portfolio of innovative assets for neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is focused on Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
The imaging study's midpoint enrollment is a significant de-risking event for the Lucid-MS program. Positive results from the completed imaging study could support the Phase 2 trial design and potentially provide a faster path to regulatory approval. For investors, this reduces uncertainty around the drug's mechanism of action in humans.
Beyond MS, the implications extend to the broader field of neuroimaging. A validated PET tracer for demyelination could become a standard tool for diagnosing and monitoring other demyelinating diseases, such as neuromyelitis optica and leukodystrophies. This would open new markets for imaging companies and create opportunities for software and AI firms that analyze PET data.
Quantum BioPharma also retains ownership of 19.84% of Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), which markets the OTC hangover remedy UNBUZZD™. The agreement includes royalty payments of 7% of sales until $250 million is reached, then 3% in perpetuity. Quantum retains 100% rights to develop similar products for pharmaceutical and medical uses.
The company's newsroom provides updates at https://ibn.fm/QNTM. The full press release is available at https://ibn.fm/4IZ0y.
For business leaders, this development highlights the importance of partnerships between biotech firms and academic medical centers. By leveraging Massachusetts General Hospital's imaging expertise, Quantum BioPharma is advancing a technology that could transform how MS is studied and treated. The ability to measure demyelination directly in patients could also reduce the cost and duration of clinical trials, a major concern for the pharmaceutical industry.
As the study progresses, stakeholders will watch for final imaging data and the initiation of the Phase 2 trial for Lucid-MS. If successful, Quantum BioPharma could position itself at the forefront of MS therapeutics, with a novel drug and a companion diagnostic that together offer a comprehensive approach to managing the disease.
